Using Radiation Therapy to Treat Prostate Cancer
How does radiation therapy treat prostate cancer?
Radiation therapy causes changes in the DNA of cancer cells that stop their ability to multiply and subsequently eradicate them. This makes radiation therapy very effective in achieving a definitive cure for prostate cancer. UF Health Radiation Oncology at the Davis Cancer Pavilion offers the most advanced radiation therapy treatment technologies for precision and adaptive planning, delivering effective treatment for prostate cancer at the time of diagnosis and for long-term control.
How is radiation therapy given for prostate cancer?
UF Health Radiation Oncology’s advanced, Linac-based treatment systems offer high-resolution imaging combined with real time on-line CT scans and MRI visualization and verification. These advanced radiotherapy treatment technologies are individually tailored to deliver maximal intensity while avoiding of normal healthy tissues and organs.
How long does radiation therapy take for prostate cancer?
For eligible patients, the UF Health Cancer Center Radiation Oncology team combines the use of hydrogel placement and dedicated MRI Simulation in a moderate hypofractionated accelerated course of treatment that takes as little as 20 days, all in one convenient location. Many programs are now offered in short courses of daily treatments, typically spanning five to 20 days. These individualized, adaptive programs are efficient, effective and diminish short-term side effects while preserving long-term quality of life.
What if I have advanced prostate cancer?
UF Health Radiation Oncology team is the first in the state of Florida to administer PLUVICTO, a next generation radiopharmaceutical used in a targeted therapy for progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Pluvicto can significantly improve survival rates for those who have limited treatment options.
Injected in six treatments at staggered intervals, the therapy allows radiation to be targeted to prostate cancer cells – with minimal effects on healthy cells – by binding to PSMA, the protein found on the surface of the cells. During the delivery of Pluvicto, imaging can identify PSMA-positive tumors through a PET scan.